• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,763.91 261.79
( 0.34%)
Global Indices
Nasdaq
52,921.07 594.83
(1.14%)
Dow Jones
7,504.24 0.01
(0.00%)
Hang Seng
69,733.68 1,000.53
(1.46%)
Nikkei 225
10,673.34 20.47
(0.19%)
Forex
USD-INR
95.28 0.28
(0.30%)
EUR-INR
108.75 0.54
(0.50%)
GBP-INR
126.99 1.06
(0.84%)
JPY-INR
0.59 0.01
(0.97%)

EQUITY - MARKET SCREENER

Marksans Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
524404
INE750C01026
36.4615746
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MARKSANS
39.76
11963.52
EPS(TTM)
Face Value()
Div & Yield %
6.64
1
0.34
 

pakka ltd
Zensar Technologies gains after appointing Brahma Pandey as Senior Vice President
Jun 16,2026
The appointment was approved by the company's board of directors through a resolution passed on 15 June 2026.

Brahma Pandey is a seasoned business and sales leader with more than 25 years of experience in the global technology services industry. He brings extensive expertise across the manufacturing and high-tech sectors and currently serves as vice president and head of sales, manufacturing, and high-tech at Infosys. Over the course of his career, Pandey has established a strong track record in driving business growth, managing large portfolios, and acquiring new clients across highly competitive markets. He is recognised for his strategic leadership, commercial acumen, and focus on delivering long-term business value and client success.

Zensar Technologies is a leading digital solutions and technology services company that conceptualizes, builds, and manages digital products through experience design, data engineering, and advanced analytics, serving over 145 global clients.

On the financial front, Zensar Technologies reported a 19.39% year-on-year increase in consolidated net profit to Rs 210.60 crore for the quarter ended March 2026, compared with Rs 176.40 crore in the corresponding quarter of the previous year. Revenue from operations rose 6.73% to Rs 1,450.40 crore from Rs 1,358.90 crore in the year-ago period.